Back to Search
Start Over
AIM reports preliminary data in Phase 1b/2 study of Ampligen, Imfinzi
- Source :
- The Fly. September 19, 2024
- Publication Year :
- 2024
-
Abstract
- AIM ImmunoTech (AIM) announced positive preliminary data from the Phase 1b/2 study evaluating the combination of AIM's Ampligen and AstraZeneca's (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.809215518